Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$760 Investment In Nanotech In The US And Russia By RUSNANO And Domain

This is a highly risky play by the state-owned Rosnano. It is good that the shareholders are unlikely to sue the management., from Western perspective, it's worth checking the protection and integrity of the intellectual property sold to the Russian side.

Russia's pharma sector is decades behind the West and has a hard time coping with Western manufacturing standards and clinical trial protocols.

Nevertheless, even if some of this biotech investment succeeds, this will be a boon for Chubais, for Rosnano, and for Russia.

Domain partners with RusNano on $760M biotech investment plan